


## Ancortave

<b>Cat. No.:</b>	HY-116098		
<b>CAS No.:</b>	10184-70-0		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>28</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	344.44		
<b>Target:</b>	Biochemical Assay Reagents		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (145.16 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.9033 mL	14.5163 mL	29.0326 mL
5 mM	0.5807 mL	2.9033 mL	5.8065 mL
10 mM	0.2903 mL	1.4516 mL	2.9033 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Ancortave (AL-4940) is an angiogenesis inhibitor. Ancortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors<sup>[1][2]</sup>.

### REFERENCES

- [1]. Kaiser PK, et al. Posterior juxtasclear depot administration of ancortave acetate. *Surv Ophthalmol.* 2007 Jan;52 Suppl 1:S62-9.
- [2]. Jockovich ME, et al. Ancortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. *Invest Ophthalmol Vis Sci.* 2006 Apr;47(4):1264-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA